496 related articles for article (PubMed ID: 33525334)
41. Critical significance of the region between Helix 1 and 2 for efficient dominant-negative inhibition by conversion-incompetent prion protein.
Taguchi Y; Mistica AM; Kitamoto T; Schätzl HM
PLoS Pathog; 2013; 9(6):e1003466. PubMed ID: 23825952
[TBL] [Abstract][Full Text] [Related]
42. Altered prion protein glycosylation in the aging mouse brain.
Goh AX; Li C; Sy MS; Wong BS
J Neurochem; 2007 Feb; 100(3):841-54. PubMed ID: 17144900
[TBL] [Abstract][Full Text] [Related]
43. Understanding the neurospecificity of Prion protein signaling.
Schneider B; Pietri M; Pradines E; Loubet D; Launay JM; Kellermann O; Mouillet-Richard S
Front Biosci (Landmark Ed); 2011 Jan; 16(1):169-86. PubMed ID: 21196165
[TBL] [Abstract][Full Text] [Related]
44. Prions, prionoids and protein misfolding disorders.
Scheckel C; Aguzzi A
Nat Rev Genet; 2018 Jul; 19(7):405-418. PubMed ID: 29713012
[TBL] [Abstract][Full Text] [Related]
45. Molecular interaction between prion protein and GFAP both in native and recombinant forms in vitro.
Dong CF; Wang XF; Wang X; Shi S; Wang GR; Shan B; An R; Li XL; Zhang BY; Han J; Dong XP
Med Microbiol Immunol; 2008 Dec; 197(4):361-8. PubMed ID: 18087720
[TBL] [Abstract][Full Text] [Related]
46. Aberrant metal binding by prion protein in human prion disease.
Wong BS; Chen SG; Colucci M; Xie Z; Pan T; Liu T; Li R; Gambetti P; Sy MS; Brown DR
J Neurochem; 2001 Sep; 78(6):1400-8. PubMed ID: 11579148
[TBL] [Abstract][Full Text] [Related]
47. Cross talk between neurometals and amyloidogenic proteins at the synapse and the pathogenesis of neurodegenerative diseases.
Kawahara M; Kato-Negishi M; Tanaka K
Metallomics; 2017 Jun; 9(6):619-633. PubMed ID: 28516990
[TBL] [Abstract][Full Text] [Related]
48. Prion protein functions and dysfunction in prion diseases.
Sakudo A; Ikuta K
Curr Med Chem; 2009; 16(3):380-9. PubMed ID: 19149584
[TBL] [Abstract][Full Text] [Related]
49. Soluble dimeric prion protein binds PrP(Sc) in vivo and antagonizes prion disease.
Meier P; Genoud N; Prinz M; Maissen M; Rülicke T; Zurbriggen A; Raeber AJ; Aguzzi A
Cell; 2003 Apr; 113(1):49-60. PubMed ID: 12679034
[TBL] [Abstract][Full Text] [Related]
50. PrP Knockout Cells Expressing Transmembrane PrP Resist Prion Infection.
Marshall KE; Hughson A; Vascellari S; Priola SA; Sakudo A; Onodera T; Baron GS
J Virol; 2017 Jan; 91(2):. PubMed ID: 27847358
[TBL] [Abstract][Full Text] [Related]
51. Prion protein prevents heavy metals overloading of cells and thus protects them against their toxicity.
Prčina M; Kontseková E; Novák M
Acta Virol; 2015 Jun; 59(2):179-84. PubMed ID: 26104335
[TBL] [Abstract][Full Text] [Related]
52. The octarepeat region of the prion protein is conformationally altered in PrP(Sc).
Yam AY; Gao CM; Wang X; Wu P; Peretz D
PLoS One; 2010 Feb; 5(2):e9316. PubMed ID: 20195363
[TBL] [Abstract][Full Text] [Related]
53. Human anti-prion antibodies block prion peptide fibril formation and neurotoxicity.
Wei X; Roettger Y; Tan B; He Y; Dodel R; Hampel H; Wei G; Haney J; Gu H; Johnstone BH; Liu J; Farlow MR; Du Y
J Biol Chem; 2012 Apr; 287(16):12858-66. PubMed ID: 22362783
[TBL] [Abstract][Full Text] [Related]
54. Heterogeneity and Architecture of Pathological Prion Protein Assemblies: Time to Revisit the Molecular Basis of the Prion Replication Process?
Igel-Egalon A; Bohl J; Moudjou M; Herzog L; Reine F; Rezaei H; Béringue V
Viruses; 2019 May; 11(5):. PubMed ID: 31083283
[TBL] [Abstract][Full Text] [Related]
55. Conservation of a glycine-rich region in the prion protein is required for uptake of prion infectivity.
Harrison CF; Lawson VA; Coleman BM; Kim YS; Masters CL; Cappai R; Barnham KJ; Hill AF
J Biol Chem; 2010 Jun; 285(26):20213-23. PubMed ID: 20356832
[TBL] [Abstract][Full Text] [Related]
56. Region-Specific Sialylation Pattern of Prion Strains Provides Novel Insight into Prion Neurotropism.
Makarava N; Chang JC; Baskakov IV
Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 32012886
[TBL] [Abstract][Full Text] [Related]
57. Monoacylated cellular prion protein modifies cell membranes, inhibits cell signaling, and reduces prion formation.
Bate C; Williams A
J Biol Chem; 2011 Mar; 286(11):8752-8. PubMed ID: 21212283
[TBL] [Abstract][Full Text] [Related]
58. Fundamentals of prion diseases and their involvement in the loss of function of cellular prion protein.
Sakudo A; Ikuta K
Protein Pept Lett; 2009; 16(3):217-29. PubMed ID: 19275734
[TBL] [Abstract][Full Text] [Related]
59. Prion neuropathology follows the accumulation of alternate prion protein isoforms after infective titre has peaked.
Sandberg MK; Al-Doujaily H; Sharps B; De Oliveira MW; Schmidt C; Richard-Londt A; Lyall S; Linehan JM; Brandner S; Wadsworth JD; Clarke AR; Collinge J
Nat Commun; 2014 Jul; 5():4347. PubMed ID: 25005024
[TBL] [Abstract][Full Text] [Related]
60. Self-assembly of recombinant prion protein of 106 residues.
Baskakov IV; Aagaard C; Mehlhorn I; Wille H; Groth D; Baldwin MA; Prusiner SB; Cohen FE
Biochemistry; 2000 Mar; 39(10):2792-804. PubMed ID: 10704232
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
